Key result
Transcatheter valve therapy for valvular heart disease is a rapidly evolving field with numerous devices developed for percutaneous treatment and several progressing to randomized clinical trials.
This review provides an overview of the rapidly evolving field of transcatheter valve therapy for valvular heart disease.
Alerts clinicians to expanding percutaneous valve options in trials; leaves open comparative effectiveness until RCTs report.
There is significant interest in developing transcatheter therapy for valvular heart disease (VHD). Numerous devices have been developed for the percutaneous treatment of pulmonary and aortic stenosis as well as mitral regurgitation. Several of these devices have progressed to randomized clinical trials. These ongoing trials for aortic stenosis and mitral regurgitation will provide important insights into the durability of these therapies as well as the results following standard surgical repair. The field of transcatheter valve therapy is rapidly evolving, and this review aims to summarize the current status of the field.
No takes yet. Share an insight, caveat, or question.
Kodali et al. (2008) conducted a review in Valvular heart disease. Transcatheter valve therapy was evaluated. Transcatheter valve therapy for valvular heart disease is a rapidly evolving field with numerous devices developed for percutaneous treatment and several progressing to randomized clinical trials.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: